Sir Gregory Winter FRS - Free Public Evening Lecture

20 December 2019


Receive more stories like this from SCI via email


Invitation to SCI’s Free Public Evening Lecture:
Sir Gregory Winter FRS – Fellow of Trinity College Cambridge and former Master of the College from 2012 -2019
The antibody revolution, its origin, propagation and impact on the pharmaceutical industry

Diary date: Wednesday 25 March 2020 SCI headquarters 18:00 for 18:30 start

  • Genetic engineering technologies have led to the development of antibodies as a new class of pharmaceutical drug.
  • These drugs have application across a wide range disease area.
  • Start-up companies were responsible for the early developments in this area, but big pharmaceutical companies were slow to get involved with the new science.

The application of genetic engineering technologies has led to the development of antibodies as a new class of pharmaceutical drugs. Many of the best selling drugs are now antibodies, particularly for the treatment of auto-immune inflammatory conditions such as rheumatoid arthritis and cancer.

Continuing scientific advances are opening up new prospects for antibody therapeutics and for other peptide and protein-based drugs. These pivotal developments had their genesis in academia and biotechnology companies, but uptake by the large pharmaceutical companies was slow.

During this Public Evening Lecture Sir Gregory will discuss the way in which this technology originated and was propagated. He will also discuss the impact of start-up companies and licensing strategies on the development of this market, the pharmaceutical companies and on the potential for further improvements.

About the speaker

Awarded the 2018 Nobel Prize in Chemistry along with George Smith and Frances Arnold, Sir Gregory Paul Winter FRS is a molecular biologist best known for his work on protein engineering and developing technologies to make therapeutic monoclonal antibodies (mAbs). He is credited with inventing techniques both to humanise rodent mAbs (1986) and to create fully human mAbs (1990). Sir Gregory was specifically cited in the Nobel Prize for ‘the phage display of peptides and antibodies’, the technology that led to the fully human antibody Humira, which is now the world’s top selling pharmaceutical drug.

Sir Gregory’s research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering in Cambridge, England.  He founded three Cambrigde-based start-up companies to help develop therapeutic drugs based on his discoveries.

Date for your diary: Wednesday 25 March 2020
Venue: SCI HQ Belgrave Square, London SW1X 8PS        

Reception opens at 18:00 and the lecture starts at 18:30. This is a free event. Registration will be opening soon!

Notes to editors:

About SCI: where science meets business

SCI is a unique global multidisciplinary network connecting scientists, business people, students and other key players involved in science-based innovation. SCI promotes innovation via its international network to advance the commercial application of science into industry for the benefit of society.

SCI works across crucial sectors as diverse as food and bio-renewables, water, environment, energy, materials and manufacturing, and health and wellbeing.

Media contact

Digital Media

Email us

Become an SCI Member to receive benefits and discounts

Join SCI